Prostate Cancer Therapeutics

Publication Date	April 2009
Publisher	Global Industry Analysts
Product Type	Report
Pages	739
ISBN Number	not applicable
Product Code	GIA01245

Buy this product or for assistance call +44 20 7060 7474

PDF £2,375.00$3951 | €2658

PRINT £2,375.00$3951 | €2658

FAX Order above formats by FAX

Summary

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Millions. Analytics in the report specifically focuses on revenues generated from hormonal therapies.The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2006 through 2015. The report profiles 138 companies including many key and niche players worldwide such as Abbott Laboratories, terna Zentaris Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC., Medimmune, LLC, Bristol-Myers Squibb Company, Cell Genesys Inc., Dendreon Corporation, EUSA Pharma, (USA) Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc., Immunomedics, Inc., Indevus Pharmaceuticals Inc., Novartis AG, OSI Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Progenics Pharmaceuticals, Inc., Sanofi-Aventis SA, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Content

I. Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Product Definitions and Scope of Study
- Hormonal Therapy
- Radiation Therapy
- Chemotherapy
- Surgical Procedures
- Other Treatment Options
II. Executive Summary
- 1.Industry Overview
  - A Prelude...
  - New Products to Bolster Sales of Prostate Cancer Therapeutics
  - Key Prostate Cancer Drugs & Companies
  - Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market
  - Select Prostate Cancer Hormonal Therapy Drugs with Year of FDA Approval
  - Targeted Therapy - The New Frontier of Cancer Treatment
  - Radiotherapy - Gaining Prominence
  - Innovations in Drug Delivery: A Key Factor in Product Differentiation
  - New Therapies Appear over the Horizon
  - New Generation Prostate Cancer Drugs and Their Area of Use
  - Small Cap Companies: A Target of Private Capital Financing
  - Drugs (that are both available and under pipeline) Developed by the Three Small-Cap Companies
  - Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets
  - Awareness Drives European Prostate Cancer Therapeutics Market
  - Growth Drivers
  - Rise in Prostate Cancer Incidences & Access to Modern Therapeutics Foster Growth
  - Demographics & Lifestyles Raise the Risk of Prostate Cancer
  - Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
  - Unmet Needs Leave Scope for Further Research and Development
  - Supportive Cancer Drugs Contribute to Growth
  - Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
  - Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
  - Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
  - Growth Restraints
  - Limited Tumor Specificity and Toxicity
  - Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  - Multiple Drug Resistance
  - Stringent Regulations Delay Market Approval
  - Ongoing Clinical Trials in Hormone Refractory Prostate Cancer
  - Challenges Encountered in Clinical Trials
  - Notable Prostate Cancer Drug Failures in Phase III Development
  - High Development Costs Retracts Manufacturers in Developing Countries
- 2.Clinical Trials
  - Drugs in Pipeline
  - Select Prostate Cancer Drugs/Compounds in Pipeline
  - Select Prostate Cancer Drugs under Phase II/III Trials by Leading Companies
  - Drugs in Pre-Clinical Stage
  - Select Prostate Cancer Drugs/Compounds in Pre-Clinical Stage
  - Commercially Available Drugs
  - Select Prostate Cancer Drugs (Commercially Available) by Leading Companies
- 3.Product Overview
  - Cancer: A Major Health Crises in the Modern World
  - Prostate - Structure
  - Pituitary Gland
  - Testes
  - Prostate Cancer - A Primer
  - Key Facts to Gaze at
  - Screening/Detection of Prostate Cancer
  - Digital Rectal Exam (DRE)
  - Transrectal Ultrasound (TRUS)
  - PSA Blood Test
  - Strategies to Enhance Screening/Detection of Prostate Cancer
  - Improved PSA Testing
  - Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels
  - Insulin-like Growth Factor (IGF-1) and Intact IGF- Binding Protien-3 (IGF-BP3)
  - GSTP1 Methylation Levels and Prostate Cancer Diagnosis
  - Microbubble Ultrasound
  - Staging of Prostate Cancer
  - Gleason Score
  - Gleason Score and Grading of Prostate Cancer
  - TNM Staging
  - T-Staging Analysis of Prostate Cancer
  - Genetic & Non-Genetic Factors
  - Hereditary or Genetic Factors
  - Non-Genetic or Environmental Factors
  - Prevention of Cancer
  - Role of Diet in Prostate Cancer
- 4.Treatment Options for Prostate Cancer
  - Hormonal Therapy
  - Medical Hormone Therapy
  - LHRH Analogs
  - Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment
  - Anti-Androgens
  - Leading Non-Steroidal Anti-androgen Hormonal Therapy Drugs for Prostate Cancer
  - Anti-Androgen Monotherapy
  - Orchiectomy
  - Side Effects of Orchiectomy
  - Time to Start Hormonal Therapy
  - Strategies to Enhance Hormonal Treatment
  - Combination Therapy
  - Intermittent Therapy
  - Radiation Therapy
  - Brachytherapy
  - Treatment Procedure
  - Benefits of Brachytherapy
  - Drawbacks of Brachytherapy
  - High Dose Rate (HDR) Brachytherapy
  - External Beam Radiation Therapy (EBRT)
  - Side Effects of Radiotherapy
  - Strategies to Enhance Radiation Treatment
  - New Radiation Techniques
  - Whole Pelvic Radiation Therapy (WPRT)
  - New Radiation Devices
  - Chemotherapy
  - Risks Associated with Chemotherapy
  - Surgical Procedures for Prostate Cancer
  - Transurethral Resection of the Prostate (TURP)
  - Prostatectomy and Lymph Node Dissection
  - Radical Prostatectomy
  - Cryosurgery
  - Advantages of Cryosurgery
  - Disadvantages of Cryosurgery
  - Other Treatment Options
  - Intensity Modulated Radiation Therapy (IMRT)
  - Benefits of IMRT
  - Drawbacks of IMRT
  - Androgen Deprivation Therapy (ADT)
  - High Dose Radiation (HDR) Monotherapy
  - Drawbacks of HRD
  - Choosing the Optimal Treatment Method...
  - Recurrent Prostate Cancer
  - Recurrent Prostate Cancer Subsequent to Surgery
  - Recurrent Prostate Cancer Subsequent to Radiation Therapy
  - Hormone-Refractory Prostate Cancer (HRPC)
  - Select Drugs in Advanced Development Stage for Hormone-Refractory Prostate Cancer
  - Chemotherapy
  - TCaxotere (Docetaxel)
  - Bone Complication Treatments
  - Bisphosphonate Drugs
  - Doxazosin, a Cytotoxic Drug for Prostate Cancer
  - Radiation Therapy
  - Strategies to Enhance Recurrent Prostate Cancer Treatment
  - Chemotherapy - New Regimens
  - Phase I Clinical Trials
  - Combination Therapy
  - Gene Therapy
  - Targeted Therapy
  - Selective Endothelia A Receptor Antagonist - (SERA)
  - Other Select Targeted Therapies
  - Tyrosine Kinase Inhibitors
  - Anti-Angiogenic Drugs
  - Monoclonal Antibodies
  - Vaccines
  - Radioactive Monoclonal Antibodies
- 5.Drug Approvals and Clinical Studies
  - Debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer Treatment
  - Algeta to Start Clinical Study of Alpharadin in HRPC
  - Ferring Receives FDA Approval for Degarelix in Prostate Cancer
  - Isis and OncoGenex Reveals Positive results of OGX- 011 Molecule in HRPC
  - Antisoma Completes Phase 2 Study of ASA404 in Prostate Cancer
  - Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate Cancer
  - Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate Cancer
  - Peregrine Pharmaceuticals Reveals Pre-Clinical Data on Bavituximab in Prostate Cancer
  - Cell Genesys Reveals Data of GVAX Immunotherapy for Treatment of Prostate Cancer
  - Bioponic Phytoceuticals Unveils Pre-Clinical Data on Curecumin for Prostate Cancer
  - New Study Reveals Cough Medicine - Noscapine to be Effective in Prostate Cancer
  - Fosamax Found Effective in Preventing Bone Loss in Prostate Cancer Patients
  - Genta Unveils Results of Phase II Clinical Trial of Genasense in Prostate Cancer
  - Cell Therapeutics Reveals Phase 2 Clinical Trial Results of XYOTAX in Androgen Independent Prostate Cancer Patients
  - Sanofi-Aventis' Taxotere Enhances Survival in Metastatic Prostate Cancer Patients
  - NCI Initiates Phase 2 Clinical Trial of Cytogen's QUADRAMET for HRPC
  - Cleveland BioLabs to Initiate Phase II Clinical Trial for Curaxin in HRPC
  - NeoRx Begins Clinical Study for Picoplatin in Prostate Cancer
  - Novacea Starts Phase III Clinical Trial for Treatment of Prostate Cancer
  - next Pharmaceuticals' Supplement Nexrutine Help Prevent Prostate Cancer
  - Antisoma Reveals Results from AS1404 Phase II Clinical Trial in HRPC
  - Marshall Edwards Conducts Study on Phenoxodiol in Prostate Cancer
  - Combination of Provenge and Taxotere Offer Better Results for HRPC Patients
  - Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy
  - University of California's Analyses Support Dendreon's Active Cellular Immunotherapy
  - Spectrum Announces Positive Outcome of Satraplatin Trial on HRPC Patients
  - Panacea Pharmaceuticals Identifies Blood Protein for Early Prostate Cancer Detection
  - Active Biotech Reveals Results of TASQ Phase I Study for Prostate Cancer
  - Positive Results of Combined Hormone and Radiation Therapies in Locally Advanced Prostate Cancer
  - Positive Results from Use of IMRT in Localized Prostate Cancer
  - Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to Reduce Prostate Cancer Growth
  - Sanofi's Taxotere Gains Approval from Nice of UK for Use in Late-Stage Prostate Cancer
  - Protox Gains Clearance from FDA to Conduct Phase I Trial of PRX302
  - terna Zentaris's Ozarelix Phase II Trial Shows Positive Results
  - Biomira Announces Results of Stimuvax Phase 2 Clinical Study
  - Cytogen Receives FDA Clearance for CYT-500 IND Application
  - US Researchers Unveils New Therapeutic Cancer Vaccine for Metastatic Prostate Cancer
  - PNNL and IsoRay Develops Cesium-131 Seed for Treatment of Prostate Cancer
- 6.Product Innovations/Introductions
  - Speciality European Pharma Introduces Plenaxis
  - Actavis Unveils Bicalutamide Tablets for Prostate Cancer in the European Markets
  - Artemis to Introduce IGRT
  - Immunomedics Introduces Immunotoxin for Treatment of Prostate and Lung Cancer
  - Barr Unveils Generic Version of Proscar Tablets
  - IRX Therapeutics to Develop Vaccine for Prostate Cancer
  - Actavis Introduces New Generic Drugs in Europe
  - Robot-Assisted Radical Prostatectomy for Treatment of Prostate Cancer
- 7.Recent Industry Activity
  - Sanofi-Aventis Secures Approval of Japanese Health Ministry for Taxotere Injection
  - Schering-Plough Terminates Collaboration with Novacea
  - Takeda Terminates JV Deal, Merges its Subsidiaries
  - Aureon Laboratories and Pfizer Announce Research Partnership
  - Celera Enters into Licensing Agreement with Merck
  - Celera Announces Demerger from Applera Corporation
  - GPC Biotech and Celgene Terminate Agreement for Satraplatin
  - EUSA Acquires Cytogen Corporation
  - Eisai Acquires MGI Pharma
  - BN ImmunoTherapeutics Enters into a Scientific Partnership with NCI
  - Morphotek Enters into Licensing Agreement with NCI
  - ValiRx Acquires Exclusive Evaluation License from CRT for New Prostate Cancer Compound
  - Cell Genesys Forms Global Alliance with Takeda on GVAX Immunotherapy Development for Prostate Cancer
  - Sirnaomics Extends Partnership with GRL to Develop Multi-Targeted RNAi Therapeutic Products
  - Aureon and Pfizer to Collaborate on New Stage of Research Project
  - CancerPartners UK Collaborates with Spire Healthcare
  - Cougar Biotech Enters into an Agreement with US FDA
  - Scottish Scientists Receives Contract from Cancer Research UK
  - ValiRx Collaborates with University of Surrey on Prostate Cancer Diagnostics
  - ValiRx Subsidiary Extends Collaboration with Cancer Research Technology
  - MacroArray Partners with Abbott on PCADM-1 Test for Prostate Cancer
  - Novacea Enters into Agreement with Schering-Plough
  - Bayer to Stop Sale of Viadur - A Drug for Prostate Cancer
  - Sagemark Embarks on Radiation Therapy Venture
  - RTS Concludes Californian Radiation Therapy Center Acquisition
  - Radiation Therapy Takes over a North Carolina Treatment Center
  - DRAXIMAGE and Med Discovery Enter into Research Collaboration
  - Core Oncology Completes Acquisition of Coloplast's Brachytherapy Business
  - Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough
  - Bentley Receives Approval for Generic Version of Casodex
  - GSK Acquires Praecis Pharmaceuticals
  - Samaritan Acquires Metastatin Pharma
  - Champions Biotechnology Acquires Patent Rights for Potential Cancer Treatments
  - GPC Biotech Submits NDA for Treatment of Prostate Cancer
  - MedMira Inks Agreement to Take over Rights of a New Marker Technology
  - Cell Genesys's GVAX Prostate Cancer-Treatment Attains FDA's Fast Track Tag
  - Envisioneering Medical Enters into Agreement with BrachySciences
  - Signet Enters into Agreement with AsymmetRx to Distribute 'Prostate-63' Tests
  - Mylan Pharmaceuticals Obtains FDA Approval for Finasteride's ANDA
  - terna Zentaris Enters into Agreement with Nippon Kayaku
  - Progenics Pharmaceuticals Broadens Association with Seattle Genetics
  - Diosynth and Dendreon Sign Multi-Year Commercial Supply Deal
  - Genstar Capital Completes Acquisition of OnCure
  - Generex Biotechnology Expands Antigen Express Cancer Trials
  - Progenics Pharmaceuticals Acquires PSMA Development Company
  - Schweizerhall Acquires Novosis
  - Misonix Expands into France with Sonablate 500
  - Indevus Enters into Agreement to Takeover Valera
  - Oncobionic Receives FDA Clearance for Cancer Treatment Technology
  - Misonix Expands HIFU Business in Europe by Entering into Spain
  - Altana Divests Entire Stake in GPC Biotech
  - Ipsen Enters into Partnership with GTx to Develop and Market Acapodene in Europe
  - Egenix and Proteome Systems Collaborate to Develop Prostate Cancer Test Using Semen
  - Valera and Spepharm Partner to Market Vantas, and Supprelin-LA
  - SurModics and AbbeyMoor Collaborate to Develop Products to Treat Prostate Diseases
  - Dendreon Constructs Manufacturing Facility in New Jersey
  - MediGene Introduces Prostate Cancer Drug in Italian Market
  - Gen-Probe Introduces Innovative Test for Prostate Cancer in Europe
  - DRL Introduces Generic Version of Proscar
  - Ferring Partners with Astellas on Degarelix License for Prostate Cancer Treatment
  - Protox Acquires PRX321 Cancer Program from US Public Health Service and Neurocrine
  - Astex Collaborates with CRT and Newcastle University for New Drug Discovery
  - Miraculins and Duke University Enter into Collaboration
  - Bayer Receives Rights to Prostate Cancer and Transplantation Drug Test from Abbott
  - Encorium Group Signs Contract with Global Biopharmaceutical Company
  - Paladin Signs an Agreement with Watson for Supply and Sale of Trelstar
  - BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko
  - OncoGenex and Isis Pharmaceuticals Expand Partnership
  - Caprion and AstraZ eneca Enter into Collaboration
  - Innovate Oncology and Prostagenics Enter into Capridine- Beta Development Agreement
  - Protein Design Labs Sublicenses Antibody-Drug Conjugates Development Rights to Genentech
  - National Cancer Institute Enters into Agreement with Illumina
  - Sosei Seeks Marketing Rights for Prostate Cancer Drug in Japan
- 8.Focus on Select Global Players
  - Abbott Laboratories (USA)
  - terna Zentaris Inc.
  - ALZA Corporation (USA)
  - Amgen Inc. (USA)
  - AstraZeneca PLC (UK)
  - Medimmune, LLC (USA)
  - Bristol-Myers Squibb Company (USA)
  - Cell Genesys Inc. (USA)
  - Dendreon Corporation (USA)
  - EUSA Pharma, (USA) Inc. (USA)
  - F. Hoffmann-La Roche Ltd. (Switzerland)
    - Genentech Inc. (USA)
    - GlaxoSmithKline Plc (UK)
    - Immunomedics, Inc. (USA)
    - Indevus Pharmaceuticals Inc. (USA)
    - Novartis AG (Switzerland)
    - OSI Pharmaceuticals, Inc. (USA)
    - Paladin Labs Inc. (Canada)
    - Pfizer Inc. (USA)
    - Progenics Pharmaceuticals, Inc. (USA)
    - Sanofi-Aventis SA (France)
    - Spectrum Pharmaceuticals, Inc. (USA)
    - Takeda Pharmaceutical Company Limited (Japan)
- 9.Global Market Perspective
III. Market
- 1.The United States
  - A. Market Analysis
    - Overview
    - A Surging US Prostate Cancer Therapeutics Market
    - Cost of Cancer Drugs - A Major Concern in the US
    - Market Accelerators
    - Market Challenges
    - Market Inhibitors
    - Current and Future Analysis
    - Key Statistics
    - Clinical Trials
    - Product Launches
    - Strategic Corporate Developments
    - Select Players
  - B. Market Analytics
- 2.Europe
  - A. Market Analysis
    - Overview
    - Awareness Drives European Prostate Cancer Therapeutics Market
    - Current and Future Analysis
    - Clinical Trial
    - Product Launches
    - Strategic Corporate Developments
  - B. Market Analytics
- 2a.France
  - A. Market Analysis
    - Overview
    - Anti-Androgen and LHRH Analogs Drive the French Market
    - Current and Future Analysis
    - Clinical Trials
    - Strategic Corporate Developments
    - Select Players
  - B. Market Analytics
- 2b.Germany
  - A. Market Analysis
    - Current and Future Analysis
    - Product Launch
    - Strategic Corporate Developments
    - GPC Biotech AG - A Major Player
  - B. Market Analytics
- 2c.Italy
  - A. Market Analysis
    - Italian Prostate Cancer Therapeutics Market - An Overview
    - Current and Future Analysis
    - Clinical Trial
    - Strategic Corporate Development
  - B. Market Analytics
- 2d.The United Kingdom
  - A. Market Analysis
    - Overview
    - LHRH Analogs - The Market Driver
    - Current and Future Analysis
    - Clinical Trials
    - Product Launch
    - Strategic Corporate Developments
    - Select Players
  - B. Market Analytics
- 2e.Spain
  - A. Market Analysis
    - Overview
    - Spanish Prostate Cancer Therapeutics Market - on a Roll
    - Current and Future Analysis
    - Strategic Corporate Developments
  - B. Market Analytics
- 2f.Rest of Europe
  - A. Market Analysis
    - Current and Future Analysis
    - Clinical Trials
    - Strategic Corporate Development
    - Select Players
  - B. Market Analytics
- 3.Rest of World
  - A. Market Analysis
    - Current and Future Analysis
    - A Peek into Canadian Market
    - Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate Cancer
    - Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy
    - Select Canadian Players
    - A Glance into Other Select Markets
    - Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets
    - Cancer Market in Asia
    - Australia
    - India
    - Japan
    - Malaysia
    - Cancer Market in Latin America
    - Brazil
    - Mexico
    - Argentina
    - Clinical Trial
    - Product Launch
    - Strategic Corporate Developments
    - Select Players
  - B. Market Analytics
IV. Competitive Landscape
List of Tables
- Table 1: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart)
- Table 2: New Incidences of Prostate Cancer (in '000) Worldwide for the years 2004 through 2007 (includes corresponding Graph/Chart)
- Table 3: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart)
- Table 4: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart)
- Table 5: Male Population by Age Group in the US for the year 2007 (includes corresponding Graph/Chart)
- Table 6: Five-Year Prostate Cancer Survival Rate in the US by Race, 1975-2002 (includes corresponding Graph/Chart)
- Table 7: Five-Year Cancer Survival Rate among US Males by Type - Prostate and Testis (1996-2002) (includes corresponding Graph/Chart)
- Table 8: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003 (includes corresponding Graph/Chart)
- Table 9: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart)
- Table 10: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart)
- Table 11: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart)
- Table 12: Comparison of Mortality among African Americans and Whites by Cancer Type in the US, 2000- 2004 (includes corresponding Graph/Chart)
- Table 13: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004
- Table 14: New Incidences of Prostate Cancer (in '000) Worldwide for the years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 15: Mortality Due to Prostate Cancer (in '000) Worldwide for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 16: Male Population (in Million) for the Year 2007 for Select Regions (includes corresponding Graph/Chart)
- Table 17: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart)
- Table 18: World Recent past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/ Country - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 19: World 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 20: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart)
- Table 21: Male Population by Age Group in the US for the Year 2007 (includes corresponding Graph/Chart)
- Table 22: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart)
- Table 23: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart)
- Table 24: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart)
- Table 25: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart)
- Table 26: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart)
- Table 27: New Cases of Prostate Cancer Diagnosed in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 28: Mortality Due to Prostate Cancer in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 29: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004
- Table 30: Comparison of Mortality among African Americans and Whites by Cancer Type in the US, 2000-2004 (includes corresponding Graph/Chart)
- Table 31: Five-Year Prostate Cancer Survival Rate in the US by Race, 1975-2002 (includes corresponding Graph/Chart)
- Table 32: Five-Year Cancer Survival Rate among US Males by Type - Prostate and Testis (1996-2002) (includes corresponding Graph/Chart)
- Table 33: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003 (includes corresponding Graph/Chart)
- Table 34: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart)
- Table 35: US Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 36: New Cases of Prostate Cancer Diagnosed in Europe: Breakdown by Region/Country for the Years 2007 and 2008 (in '000) (includes corresponding Graph/Chart)
- Table 37: Mortality Due to Prostate Cancer in Europe: Breakdown by Region/ Country for the Years 2007 and 2008 (in '000) (includes corresponding Graph/Chart)
- Table 38: European Recent past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 39: European 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 40: French Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 41: German Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 42: Italian Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 43: UK Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 44: Spanish Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 45: Rest of Europe Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 46: New Cases of Prostate Cancer Diagnosed in Canada (2008): Breakdown by Leading Province (includes corresponding Graph/Chart)
- Table 47: Mortality Due to Prostate Cancer Diagnosed in Canada (2008): Breakdown by Leading Province (includes corresponding Graph/Chart)
- Table 48: Prostate Cancer Market in Canada (2008): New Cases and Deaths Due to Prostate Cancer by Age Group
- Table 49: New Cases of Prostate Cancer Diagnosed in Asia-Pacific: Breakdown by Region/Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 50: Mortality Due to Prostate Cancer in Asia-Pacific: Breakdown by Region/ Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 51: New Cases of Prostate Cancer Diagnosed in Latin America: Breakdown by Region/Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 52: Mortality Due to Prostate Cancer in Latin America: Breakdown by Region/ Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
- Table 53: Rest of World Recent past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)